临床试验/NCT05411237

NCT05411237尚未招募3 期

A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings

AIDS Malignancy Consortium0 个研究点目标入组 130 人开始时间: 2026年9月1日最近更新: 2026年1月23日

适应症

干预措施

试验速览

阶段: 3 期
状态: 尚未招募
发起方
入组人数: 130
主要终点: Progression Free Survival at 48 weeks

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This study is being done to determine if two different anti-cancer drugs, paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) have similar effects on treating Kaposi Sarcoma (KS) in people living with HIV (human immunodeficiency virus) in sub-Saharan Africa. Patients with HIV-related KS will receive either PTX or PLD once every 3 weeks for a total of six cycles.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•HIV-1 infection.
•Histologically confirmed KS at any time prior to study entry, confirmed by an AIDS Malignancy Consortium (AMC)-certified pathologist.
•Current stage T1 KS (irrespective of prior treatment with antiretroviral therapy (ART) OR
•Stage T0 KS that has progressed or not responded after a minimum of 12 weeks of treatment with ART. Participants with T0 KS must have either:
•20 or more skin and/or oral KS lesions, and/or
•any number of lesions on exposed body areas that have an adverse effect on quality of life (e.g., stigmatization).
•Men and women ≥ 18 years. Because no dosing or adverse event data are currently available on the use of PTX or PLD for AIDS-KS in persons <18 years of age, children are excluded from this study
•Karnofsky performance status ≥ 60 (ECOG ≤ 2).
•Echocardiogram or Multiple gated acquisition scanning (MUGA) showing an ejection fraction ≥ 50%.
•Ability and willingness of participant or legal guardian to provide informed consent.
•Participants may be ART-naïve or ART-experienced but must be able to receive an ART regimen considered likely to result in HIV suppression.
•Measurable cutaneous KS, defined as follows:
•When available, a minimum of five bi-dimensionally measurable KS cutaneous marker lesions.
•If fewer than five bi-dimensionally measurable marker lesions are available, the total surface area of the marker lesion(s) must be ≥ 700mm
•The following laboratory values obtained within 14 days prior to study entry:
•Absolute Neutrophil Count ≥ 1000 cells/mm
•Hemoglobin ≥ 8 g/dL (may be achieved with transfusion if clinically indicated, in the opinion of the investigator).
•Platelet count ≥ 75,000/mm
•ALT, AST, Alkaline phosphatase < 5 × upper limit of normal (ULN).
•Total bilirubin: ≤ 1.5 × ULN, unless the participant is receiving an antiretroviral drug known to be associated with increased bilirubin, in which case the direct fraction should be ≤ 2 x the ULN.
•Creatinine < institutional ULN OR estimated glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
•Women of reproductive potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months), must have a negative pregnancy test done within 24 hours of initiating the protocol-specified chemotherapy medication.
•Participants must agree to use two reliable forms of contraception simultaneously while receiving study protocol-specified medication and for 6 months after stopping the medication.
•Adequate venous access.
•No prior chemotherapy or use of systemic cytotoxic therapy agents.
•Participant is able to understand and willing to sign a written informed consent document.

排除标准

•Current acute, chronic, or recurrent infections that are serious, in the opinion of the site investigator, for which the participant has not completed at least 14 days of therapy before study entry and/or is not clinically stable.
•Serious illness necessitating hospitalization/systemic treatment within 14 days prior to study entry
•Breastfeeding or pregnant women are excluded because of potential risks of cytotoxic chemotherapy to an unborn child or infant.
•Known history of congestive heart failure and/or systolic ejection fraction < 50%.
•Prior radiotherapy to KS indicator lesions
•Prior or current immunotherapy
•Any immunomodulator, HIV vaccine, live attenuated vaccine, other investigational vaccine within 30 days prior to study entry, excluding vaccines against COVID-19/SARS-CoV-2, which are permitted.
•Known allergy/hypersensitivity to the study drug or its formulation
•Any condition, including the presence of laboratory abnormalities, which in the opinion of the responsible investigator places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
•Corticosteroid use at doses above those given for replacement therapy for adrenal insufficiency within the last 30 days prior to study entry.
•Patients with psychiatric illness and/or social circumstances that would limit compliance with study requirements.

研究组 & 干预措施

Pegylated Liposomal Doxorubicin

Active Comparator

Participants will receive a single intravenous dose of PLD 20 mg/m2 once every 3 weeks for a total of 18 weeks.

干预措施: Pegylated liposomal doxorubicin (Drug)

Paclitaxel

Active Comparator

Participants will receive a single intravenous dose of PTX 100 mg/m2 once every 3 weeks for a total of 18 weeks.

干预措施: Paclitaxel (Drug)

结局指标

主要结局

Progression Free Survival at 48 weeks

时间窗: 48 weeks

Progression free survival (PFS) is defined as the length of time from enrollment into the study until disease progression or death. Disease progression will be assessed using the Kaposi Sarcoma Response Evaluation Criteria. Progressive disease is defined as: 1) 25% increase in the sum of perpendicular diameters of the indicator lesions; 2) 25% increase in the total number of KS lesions or the appearance of 5 new lesions; OR 3) 25% increase in the number of raised lesions

次要结局

Objective response rate for AIDS-related KS in patients receiving PLD and PTX(96 weeks)
Duration of Response in patients receiving PLD and PTX(96 weeks)
Frequency and severity of adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 in participants receiving PLD or PTX.(96 weeks)

研究者

发起方

AIDS Malignancy Consortium

申办方类型

Network

责任方

Sponsor

相似试验

已完成

2 期

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast CancerBreast Cancer

NCT00320541Eli Lilly and Company187

终止

不适用

A phase III clinical study to compare paclitaxel (Genexol®-PM) in combination with standard therapy (gemcitabine/cisplatin) and standard therapy alone (gemcitabine/cisplatin) in patients with advanced biliary tractNeoplasms

KCT0003726Asan Medical Center220

Unknown

3 期

NCT00954174GOG Foundation637

已完成

2 期

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine CancerSarcoma

NCT00112489Gynecologic Oncology Group55

已完成

3 期

Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung CancerLung Cancer

NCT00193362SCRI Development Innovations, LLC200